Q-omics provides the consensus-scored LINC02481 profile across patient tissues and cancer cell-line models. LINC02481 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, LINC02481 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, LINC02481 RNA expression shows 18,310 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, KIRC, and UVM as cancer lineages where LINC02481 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02481 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02481 survival associations across molecular data types. LINC02481 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02481 RNA expression–survival associations across cancer types. High LINC02481 expression shows unfavorable associations in UVM, but favorable associations in HNSC, SKCM, CESC, BLCA and READ. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for LINC02481 RNA expression.
This table summarizes LINC02481 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02481. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02481 shows lower tumor expression in LUSC and higher tumor expression in KIRC, COAD, BRCA, STAD and THCA. The KIRC box plot shows higher LINC02481 RNA expression in tumor versus normal tissue (log2 FC = +0.385, t-test p < 0.001).
This table shows molecular features associated with LINC02481 in patient tissues and cancer cell lines. In patient samples, LINC02481 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
